Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes.
about
Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011HIV-1 diversity and drug resistance mutations among people seeking HIV diagnosis in voluntary counseling and testing sites in Rio de Janeiro, BrazilSVARAP and aSVARAP: simple tools for quantitative analysis of nucleotide and amino acid variability and primer selection for clinical microbiology.Costs and benefits of multiple resistance to insecticides for Culex quinquefasciatus mosquitoes.Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysisIn vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy.Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in ChinaThe successful application of a national peer advisory committee for physicians who provide salvage regimens to heavily antiretroviral-experienced patients in mexican human immunodeficiency virus clinicsDoes palliative care improve outcomes for patients with HIV/AIDS? A systematic review of the evidence.Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in MoroccoAccess and equity in HIV/AIDS palliative care: a review of the evidence and responses.Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.Emergence of clusters of CRF02_AG and B human immunodeficiency viral strains among men having sex with men exhibiting HIV primary infection in southeastern France.In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile.Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs.HIV drug resistance in newly diagnosed adults in a rural prefecture of eastern China.Synthesis and anti-HIV-1 screening of novel N'-(1-(aryl)ethylidene)-2-(5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-4(1H)-yl)acetohydrazides.The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in PortugalIn vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs.
P2860
Q28488769-7628D5B2-3220-4E95-A290-2AF7B185544AQ28539348-1A1DCD37-E408-4DE0-8788-57D7B3286ED5Q30810347-99522AF4-BAA3-41FE-875C-D606736E3DDDQ33327304-4FA0C02D-8D85-485E-AB14-3FB216235902Q33988153-7325C6BA-5E37-46A3-B399-BE2E4A353823Q34352006-CD56693F-F88A-491F-B525-EE3C9D66BB00Q34468059-B5B7AAE8-F9D5-4D89-80FD-9D8DFB61FEFCQ34523956-0EEDBBC9-047B-45D0-A27B-33320F0F7D2BQ34802051-040AC8E3-6188-46A4-AC72-3CEAE13BBE34Q35572961-A2A40445-6952-493A-858E-B7A5E2240E05Q36069767-9292D268-0D60-4F71-B00A-34AA093E0BE7Q36102579-1F531C06-8C74-411A-87E2-18A78F60ED5EQ36141864-7BF133A8-980D-4CFD-830D-E094779DB05FQ36425068-57C59624-505B-4A8E-949D-C0F494871EFEQ36506829-FFB07F2F-A823-478D-8783-FDF22E25DC5DQ36836868-D883879F-94C5-4F46-A2D4-DF82E6475408Q39470044-2547A5F2-FE87-4C5C-A4FE-54610BFB3CFFQ39507516-FC45AE25-65E6-4969-AFF3-7D148B699A20Q41875646-FA8A4CD3-75A3-433E-A54E-357D506FF170Q42178078-DDFE8E2E-37A6-469A-AD8E-05426A8C6832Q42215138-6FB61D7B-F41E-4986-8451-5C8F8C36090CQ42285294-29C30869-9BE6-40F6-84A1-B41B57775A20Q42742963-B27B6AE3-4DBF-4283-8FC9-E39134D52304Q44552532-F3412C8C-E5AD-4F6F-BE7D-9A8EE39027F4
P2860
Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Resistance of HIV-1 to multipl ...... alysis of over 7000 genotypes.
@en
Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey
@nl
type
label
Resistance of HIV-1 to multipl ...... alysis of over 7000 genotypes.
@en
Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey
@nl
prefLabel
Resistance of HIV-1 to multipl ...... alysis of over 7000 genotypes.
@en
Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey
@nl
P2093
P1433
P1476
Resistance of HIV-1 to multipl ...... alysis of over 7000 genotypes.
@en
P2093
Catherine Tamalet
Christian Tourres
Jacques Fantini
Nouara Yahi
P304
P356
10.1097/00002030-200311070-00014
P407
P577
2003-11-01T00:00:00Z